# US 2015/0104381 A1 · Enhanced in vivo Targeting of Radiolabelled Peptides with the Means of Enzyme Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104381 A1
- Document ID: US20150104381A1
- Status: Published application
- Kind: A1
- Application number: 14/131,573
- Filed: 2012-07-06
- Published: 2015-04-16
- Earliest claimed: 2011-07-08
- Assignees: BioSynthema Inc.
- Inventors: Theodosia Maina-Nock; Berthold Artur Nock; Marion de Jong Hendriks
- Web page: https://patentgrep.com/patent/US20150104381A1

## CPC

- A61K 51/085: {the peptide being neurotensin}
- A61K 31/265: of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
- A61K 31/7028: Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 51/08: Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins}
- A61K 51/083: {the peptide being octreotide or a somatostatin-receptor-binding peptide}
- A61K 51/086: {the peptide being alphaMSH, alpha melanocyte stimulating hormone}
- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a compound that inhibits the activity of a degrading enzyme for use in combination with a therapeutic or diagnostic compound, preferably a moiety conjugated peptide, in the diagnosis and/or treatment of a disease, in particular cancer, to enhance targeting of the therapeutic or diagnostic compound to the disease site.

## Claims

### Claim 1

Compound that inhibits the activity of a degrading enzyme for use in combination with a therapeutic or diagnostic compound, preferably a moiety conjugated peptide, in the diagnosis and/or treatment of a disease, in particular cancer, to enhance targeting of the therapeutic or diagnostic compound to the disease site.

### Claim 2 (depends on 1)

Compound as claimed in claim 1, wherein the degrading enzyme is a hydrolase selected from peptidases, esterases.

### Claim 3 (depends on 2)

Compound as claimed in claim 2, wherein the enzyme is a neutral endopeptidase or angiotensin converting enzyme.

### Claim 4 (depends on 1, 2, 3)

Compound as claimed in any one of the claims 1-3, wherein the therapeutic or diagnostic compound is selected from peptide conjugates, receptor ligands, peptides, peptide receptor ligand and radioactively labeled peptides.

### Claim 5 (depends on 4)

Compound according to claim 4, wherein the radioactively labeled peptide is not completely stabilized.

### Claim 6 (depends on 1, 2, 3, 4, 5)

Compound as claimed in any one of the claims 1-5, wherein the peptide is an antagonist.

### Claim 7 (depends on 1, 2, 3, 4, 5)

Compound as claimed in any one of the claims 1-5, wherein the peptide is an agonist.

### Claim 8 (depends on 1, 2, 3, 4, 5)

Compound as claimed in any one of the claims 1-5, wherein the peptide is selected from somatostatins, in particular somatostatin-14 and its analogs, CCK2R-receptor ligands, such as CCKs, gastrins, minigastrins and their analogs, in particular minigastrin(10-17), neurotensin receptor ligands, in particular neurotensin subtype 1 receptors, such as neurotensin and its analogs, demotensins and its analogs, in particular demotensin 6, gastrin releasing peptide receptor (GRPR) ligands, in particular bombesin and its analogs, in particular 99mTc-demobesin 4 and 99mTc-demobesin 1, neuromedin C (NMC) and it analogs, in particular 99mTc-SAR-NCs such as 99mTc-SAR-NC1 and 99mTc-SAR-NC6, or the JMV compounds, in particular compound 111In/177Lu/67/68Ga-JMV4168, neuropeptide substance P such as SP-1, SP-2, melanocyte stimulating hormone (MSH), chemotactic peptide (CTP) or combinations thereof.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

Compound as claimed in any one of the claims 1-8, which compound is selected from NEP inhibitors, in particular phosphoramidon, racecadotril, ACE inhibitors, in particular lisinopril, captopril, ECE inhibitors, esterase inhibitors.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7)

Compound as claimed in any one of the claims 1-7, wherein the enzyme inhibitor is a competing enzyme substrate.

### Claim 11 (depends on 10)

Compound as claimed in claim 10, wherein the competing enzyme substrate is a plasma expander selected from Haemaccel and Gelofusine.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7)

Compound as claimed in any one of the claims 1-7, wherein the enzyme inhibitor is a bait peptide.

### Claim 13

Compounds for use in combination with a diagnostic or therapeutic vector in the diagnosis or treatment of a disease, in particular cancer, that increase the uptake of said vector at the disease site(s) by inhibiting the activity of degrading enzymes.

### Claim 14

A composition comprising a therapeutic or diagnostic compound that comprises a moiety conjugated peptide, preferably a peptide-ligand conjugate, and one or more compounds that inhibit the activity of a hydrolase, wherein the hydrolase is a peptidase or an esterase.

### Claim 15 (depends on 14)

The composition of claim 14 wherein administration of the composition enhances in vivo targeting of the therapeutic or diagnostic peptide conjugate as compared to administration of just the therapeutic or diagnostic compound alone.

### Claim 16 (depends on 14, 15)

The composition of claim 14 or claim 15, wherein the peptide-conjugate is a native peptide-conjugate and biodegradable derivatives thereof.

### Claim 17 (depends on 14, 15, 16)

The composition according to any of the claims 14 to 16, wherein the therapeutic or diagnostic compound is a radiolabeled peptide conjugate, or is a peptide conjugate labeled with a fluorescent molecule for optical imaging, or is coupled to a cytotoxic moiety.

### Claim 18 (depends on 14, 15, 16, 17)

The composition according to any of the claims 14 to 17 wherein the therapeutic or diagnostic compound is a radiolabeled biodegradable peptide-conjugate derived from the group consisting of somatostatin, gastrin, neurotensin, bombesin, neuromedin C, and a gastrin releasing peptide receptor (GRPR)-antagonist.

### Claim 19 (depends on 14, 15, 16, 17, 18)

The composition according to any of the claims 14 to 18, wherein the one or more compounds that inhibit the activity of a hydrolase is selected from the group consisting of neutral endopeptidase inhibitors, angiotensin-converting enzyme inhibitors, endothelin converting enzyme inhibitors, esterase inhibitors, and combinations thereof.

### Claim 20 (depends on 14, 15, 16, 17, 18, 19)

The composition according to any of the claims 14 to 19, wherein the one or more compounds that inhibit the activity of hydrolase is a neutral endopeptidase inhibitor.

### Claim 21 (depends on 20)

The composition according to claim 20, wherein the neutral endopeptidase inhibitor is phosphoramidon or racecadotril.

### Claim 22 (depends on 14, 15, 16, 17, 18, 19, 20, 21)

The composition according to any of the claims 14 to 21, wherein the wherein the one or more compounds that inhibit the activity of a hydrolase is an angiotensin-converting enzyme inhibitor.

### Claim 23 (depends on 17)

The composition according to claim 17, wherein the radiolabeled peptide conjugate is radiometallated peptide or a peptide radiohalogenated via a prosthetic group.

### Claim 24 (depends on 17)

The composition according to claim 17, wherein the radiolabeled peptide conjugate comprises a radionuclide metal selected from the group comprising 111In, 99mTc, 94mTc, 67Ga, 66Ga, 68Ga, 52Fe, 69Er, 72As, 97Ru, 203Pb, 62Cu, 64Cu, 67Cu, 186Re, 188Re, 86Y, 90Y, 51Cr, 52mMn, 157Gd, 177Lu, 161Tb, 169Yb, 175Yb, 105Rh, 166Dy, 166Ho, 153Sm, 149Pm, 151Pm, 172Tm, 121Sn, 177mSn, 213Bi, 142Pr, 143Pr, 198Au, 199Au, 18F, 123I, 124I, 131I, 75Br, 76Br, 77Br, and 82Br.

### Claim 25 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The composition according to any of the claims 14 to 24, wherein the composition comprises a combination selected from the group of combinations consisting of: [(X-DOTA)Ala1]SS-14 or [(X-DOTA)Ala1, DTrp8]SS-14 with a neutral endopeptidase inhibitor; X-DOTA-MG11 with a neutral endopeptidase inhibitor; X-demotensin 6 or X-demotensin 1 with a neutral endopeptidase inhibitor; X-demotensin 1 with a neutral endopeptidase inhibitor and/or an ACE inhibitor; X-SAR-NC1 or X-SAR-NC6 with a neutral endopeptidase inhibitor; X-Demobesin 4 or X-Demobesin 1 with a neutral endopeptidase inhibitor; and X-JMV4168 with a neutral endopeptidase inhibitor, wherein X is a radionuclide useful for radiotherapy or imaging.

### Claim 26 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The composition according to any of the claims 14 to 25, wherein the composition comprises a combination selected from the group of combinations consisting of: [(111In-DOTA)Ala1]SS-14 or [(111In-DOTA)Ala1, DTrp8]SS-14 with a neutral endopeptidase inhibitor; 111In-DOTA-MG11 with a neutral endopeptidase inhibitor; 99mTc-demotensin 6 or 99mTc-demotensin 1 with a neutral endopeptidase inhibitor; 99mTc-demotensin 1 with a neutral endopeptidase inhibitor and/or an ACE inhibitor; 99mTc-SAR-NC1 or 99mTc-SAR-NC6 with a neutral endopeptidase inhibitor; 99mTc-Demobesin 4 or 99mTc-Demobesin 1 with a neutral endopeptidase inhibitor; and 111In-JMV4168 with a neutral endopeptidase inhibitor.

### Claim 27

A method of treating and/or diagnosing a disease comprising co-administration of a therapeutic or diagnostic compound with one or more compounds that inhibit the activity of at least one hydrolase, wherein the therapeutic or diagnostic compound comprises a biodegradable peptide-ligand conjugate and the hydrolase is a peptidase or an esterase.

### Claim 28 (depends on 27)

The method of claim 27, wherein in vivo targeting of the therapeutic or diagnostic compound is enhanced as compared to in vivo targeting of the therapeutic or diagnostic compound in an absence of said compound(s) that inhibit the activity of said hydrolase.

### Claim 29 (depends on 27)

The method of claim 27, wherein the peptide-ligand is a native peptide-ligand or not fully stabilized analog thereof conjugated to a diagnostic or therapeutic moiety.

### Claim 30 (depends on 27)

The method of claim 27, wherein the therapeutic or diagnostic compound is a peptide-ligand conjugate, radiolabeled or is labeled with a fluorescent molecule for optical imaging, or is coupled to a cytotoxic drug.

### Claim 31 (depends on 27)

The method of claim 27, wherein the therapeutic or diagnostic compound is a radiolabeled biodegradable peptide-conjugate derived from the group consisting of somatostatin, gastrin, neurotensin, bombesin, neuromedin C, and a gastrin releasing peptide receptor-antagonist.

### Claim 32 (depends on 27)

The method of claim 27, wherein the one or more compounds that inhibit the activity of a hydrolase is selected from the group consisting of neutral endopeptidase inhibitors, angiotensin-converting enzyme inhibitors, endothelin converting enzyme inhibitors, esterase inhibitors, and combinations thereof.

### Claim 33 (depends on 27)

The method of claim 27, wherein the one or more compounds that inhibit the activity of a hydrolase is a neutral endopeptidase inhibitor.

### Claim 34 (depends on 27)

The method of claim 27, wherein the neutral endopeptidase inhibitor is phosphoramidon or racecadotril.

### Claim 35 (depends on 27)

The method of claim 27, wherein the one or more compounds that inhibit the activity of a hydrolase is an angiotensin-converting enzyme inhibitor.

### Claim 36 (depends on 27)

The method of claim 27, wherein the peptide-radioligand is a radiometallated peptide or a peptide modified with a prosthetic group for incorporation of radiohalogens.

### Claim 37 (depends on 27)

The method of claim 27, wherein the peptide-radioligand comprises a radionuclide metal selected from the group comprising 111In, 99mTc, 94mTc, 67Ga, 66Ga, 68Ga, 52Fe, 69Er, 72As, 97Ru, 203Pb, 62Cu, 64Cu, 67Cu, 186Re, 188Re, 86Y, 90Y, 51Cr, 52mMn, 157Gd, 177Lu, 161Tb, 169Yb, 175Yb, 105Rh, 166Dy, 166Ho, 153Sm, 149Pm, 151Pm, 172Tm, 121Sn, 177mSn, 213Bi, 142Pr, 143Pr, 198Au, 199Au, 18F, 123I, 124I, 131I, 75Br, 76Br, 77Br, and 82Br.

### Claim 38 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 27-37, wherein the co-administration comprises:
(i) administering the therapeutic or diagnostic compound at the same time as the one or more compounds that inhibit the activity of a hydrolase;
(ii) first administering the therapeutic or diagnostic compound, followed by administering the one or more compounds that inhibit the activity of a hydrolase; or
(iii) first administering the one or more compounds that inhibit the activity of a hydrolase, followed administering the therapeutic or diagnostic compound.

### Claim 39 (depends on 27)

The method of claim 27, wherein the combination of a therapeutic or diagnostic compound and one or more compounds that inhibit the activity of a hydrolase is selected from the group of combinations consisting of: [(X-DOTA)Ala1]SS-14 or [(X-DOTA)Ala1, DTrp8]SS-14 with a neutral endopeptidase inhibitor; X-DOTA-MG11 with a neutral endopeptidase inhibitor; X-demotensin 6 or X-demotensin 1 with a neutral endopeptidase inhibitor; X-demotensin 1 with a neutral endopeptidase inhibitor and/or an ACE inhibitor; X-SAR-NC1 or X-SAR-NC6 with a neutral endopeptidase inhibitor; X-Demobesin 4 or X-Demobesin 1 with a neutral endopeptidase inhibitor; and X-JMV4168 with a neutral endopeptidase inhibitor, wherein X is a radionuclide useful for radiotherapy or imaging.

### Claim 40 (depends on 27)

The method of claim 27, wherein the combination of a therapeutic or diagnostic compound and one or more compounds that inhibit the activity of a hydrolase is selected from the group of combinations consisting of: [(111In-DOTA)Ala1]SS-14 or [(111In-DOTA)Ala1, DTrp8]SS-14 with a neutral endopeptidase inhibitor; 111In-DOTA-MG11 with a neutral endopeptidase inhibitor; 99mTc-demotensin 6 or 99mTc-demotensin 1 with a neutral endopeptidase inhibitor; 99mTc-demotensin 1 with a neutral endopeptidase inhibitor and/or an ACE inhibitor; 99mTc-SAR-NC1 or 99mTc-SAR-NC6 with a neutral endopeptidase inhibitor; 99mTc-Demobesin 4 or 99mTc-Demobesin 1 with a neutral endopeptidase inhibitor; and 111In-JMV4168 with a neutral endopeptidase inhibitor.
